Mirna Therapeutics (MIRN) Says FDA Placed MRX34 IND on Full Clinical Hold

September 29, 2016 5:06 PM EDT
Get Alerts MIRN Hot Sheet
Trade MIRN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Mirna Therapeutics (NASDAQ: MIRN) disclosed the following on Thursday:

Item 8.01 Other Events.

On September 28, 2016, Mirna Therapeutics, Inc. (the “Company”) received verbal notice from the U.S. Food and Drug Administration (the “FDA”) that the Company’s Investigational New Drug (“IND”) for MRX34, its investigational microRNA therapy for multiple cancers, has been placed on full clinical hold. The Company anticipates that it will receive a formal clinical hold letter from the FDA within 30 days. This follows the Company’s announcement on September 20, 2016 that it was voluntarily stopping its Phase 1 trial for MRX34.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News

Add Your Comment